License Agreement
Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb
Harbour BioMed; Bristol Myers Squibb; BMS; multi-specific antibodies; $90 million upfront; $1.035 billion milestones; global strategic collaboration; license agreement; Harbour Mice technology; immunology; oncology; biobucks deal; China early clinical trials
Insilico Medicine and TaiGen sign exclusive licensing deal for AI-designed PHD inhibitor ISM4808 to treat anemia in chronic kidney disease
Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech
Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases
Zealand Pharma; OTR Therapeutics; strategic collaboration; license agreement; metabolic diseases; obesity; oral small-molecule therapeutics; R&D partnership; China biotech; upfront payment; milestone payments; royalties
GSK walks away from remaining IDEAYA programs, formally ending partnership
GSK; IDEAYA Biosciences; synthetic lethality; collaboration termination; Werner helicase; Pol Theta; DNA damage repair; oncology partnership; license agreement; drug development pipeline
GSK and AnaptysBio Enter Legal Dispute Over Jemperli License Amid Allegations of Contract Breaches
GSK; AnaptysBio; Jemperli; dostarlimab; TESARO; litigation; license agreement; oncology; royalties; endometrial cancer
Sanofi Partners with EVOQ Therapeutics to Advance NanoDisc-Based Autoimmune Therapies
Sanofi; EVOQ Therapeutics; NanoDisc; autoimmune disease; license agreement; immune tolerance; celiac disease; type 1 diabetes; MOG antibody disease; rheumatoid arthritis; lupus